EVO
Price
$4.05
Change
+$0.04 (+1.00%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
2.77B
68 days until earnings call
LFCR
Price
$6.85
Change
+$0.10 (+1.48%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
176.87M
82 days until earnings call
Interact to see
Advertisement

EVO vs LFCR

Header iconEVO vs LFCR Comparison
Open Charts EVO vs LFCRBanner chart's image
Evotec SE
Price$4.05
Change+$0.04 (+1.00%)
Volume$600
Capitalization2.77B
Lifecore Biomedical
Price$6.85
Change+$0.10 (+1.48%)
Volume$6.63K
Capitalization176.87M
EVO vs LFCR Comparison Chart
Loading...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVO vs. LFCR commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Hold and LFCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (EVO: $4.05 vs. LFCR: $6.76)
Brand notoriety: EVO and LFCR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EVO: 26% vs. LFCR: 41%
Market capitalization -- EVO: $2.77B vs. LFCR: $176.87M
EVO [@Pharmaceuticals: Other] is valued at $2.77B. LFCR’s [@Pharmaceuticals: Other] market capitalization is $176.87M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVO’s FA Score shows that 1 FA rating(s) are green whileLFCR’s FA Score has 1 green FA rating(s).

  • EVO’s FA Score: 1 green, 4 red.
  • LFCR’s FA Score: 1 green, 4 red.
According to our system of comparison, LFCR is a better buy in the long-term than EVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVO’s TA Score shows that 4 TA indicator(s) are bullish while LFCR’s TA Score has 6 bullish TA indicator(s).

  • EVO’s TA Score: 4 bullish, 4 bearish.
  • LFCR’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, LFCR is a better buy in the short-term than EVO.

Price Growth

EVO (@Pharmaceuticals: Other) experienced а +2.02% price change this week, while LFCR (@Pharmaceuticals: Other) price change was -1.24% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +79.53%. For the same industry, the average monthly price growth was +16.37%, and the average quarterly price growth was +68.04%.

Reported Earning Dates

EVO is expected to report earnings on Aug 13, 2025.

LFCR is expected to report earnings on Aug 27, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+79.53% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EVO($2.77B) has a higher market cap than LFCR($177M). EVO YTD gains are higher at: -2.644 vs. LFCR (-8.950). LFCR has higher annual earnings (EBITDA): -22.64M vs. EVO (-63.26M). EVO has more cash in the bank: 619M vs. LFCR (4.22M). LFCR has less debt than EVO: LFCR (157M) vs EVO (589M). EVO has higher revenues than LFCR: EVO (821M) vs LFCR (188M).
EVOLFCREVO / LFCR
Capitalization2.77B177M1,564%
EBITDA-63.26M-22.64M279%
Gain YTD-2.644-8.95030%
P/E Ratio476.19N/A-
Revenue821M188M437%
Total Cash619M4.22M14,661%
Total Debt589M157M375%
FUNDAMENTALS RATINGS
EVO vs LFCR: Fundamental Ratings
EVO
LFCR
OUTLOOK RATING
1..100
1178
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9299
PRICE GROWTH RATING
1..100
5850
P/E GROWTH RATING
1..100
24
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LFCR's Valuation (92) in the Industrial Specialties industry is in the same range as EVO (93) in the null industry. This means that LFCR’s stock grew similarly to EVO’s over the last 12 months.

LFCR's Profit vs Risk Rating (100) in the Industrial Specialties industry is in the same range as EVO (100) in the null industry. This means that LFCR’s stock grew similarly to EVO’s over the last 12 months.

EVO's SMR Rating (92) in the null industry is in the same range as LFCR (99) in the Industrial Specialties industry. This means that EVO’s stock grew similarly to LFCR’s over the last 12 months.

LFCR's Price Growth Rating (50) in the Industrial Specialties industry is in the same range as EVO (58) in the null industry. This means that LFCR’s stock grew similarly to EVO’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is in the same range as LFCR (4) in the Industrial Specialties industry. This means that EVO’s stock grew similarly to LFCR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOLFCR
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
66%
Momentum
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 11 days ago
76%
Declines
ODDS (%)
Bearish Trend 9 days ago
79%
Bearish Trend 8 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFUVX32.000.40
+1.27%
DFA US Large Cap Value III
OAZGX35.480.37
+1.05%
Oakmark Global R6
DIECX43.74N/A
N/A
BNY Mellon International Core Equity C
VMNFX13.70N/A
N/A
Vanguard Market Neutral Inv
VSEMX227.22N/A
N/A
Vanguard Extended Market Index Instl Sel

LFCR and

Correlation & Price change

A.I.dvisor tells us that LFCR and SHPH have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LFCR and SHPH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
-1.67%
SHPH - LFCR
31%
Poorly correlated
-7.41%
ALKS - LFCR
28%
Poorly correlated
-1.73%
OGI - LFCR
27%
Poorly correlated
-2.24%
AMRX - LFCR
27%
Poorly correlated
-0.55%
TLRY - LFCR
27%
Poorly correlated
-5.40%
More